149 related articles for article (PubMed ID: 14717986)
1. A randomized, double-blind, placebo-controlled clinical trial of high-dose interferon-alpha induction treatment combined with ribavirin for chronic hepatitis C in hemophilia.
Meijer K; Haagsma EB; van der Meer J;
J Thromb Haemost; 2004 Jan; 2(1):194-6. PubMed ID: 14717986
[No Abstract] [Full Text] [Related]
2. Summaries for patients. Duration and dose of antiviral treatment for chronic hepatitis C.
Ann Intern Med; 2004 Mar; 140(5):I67. PubMed ID: 14996694
[No Abstract] [Full Text] [Related]
3. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
Sulkowski M; Pol S; Mallolas J; Fainboim H; Cooper C; Slim J; Rivero A; Mak C; Thompson S; Howe AY; Wenning L; Sklar P; Wahl J; Greaves W;
Lancet Infect Dis; 2013 Jul; 13(7):597-605. PubMed ID: 23768747
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of antiviral therapy in patients with hemophilia and hepatitis C virus infection].
Kostić V; Dordević M; Popović L; Kostić E; Dordević J; Govedarević N
Med Pregl; 2009; 62(3-4):129-32. PubMed ID: 19623841
[TBL] [Abstract][Full Text] [Related]
5. A randomized study of alpha-interferon plus ribavirin for 6 months or 12 months for the treatment of chronic hepatitis C in patients with bleeding disorders.
Schulman S; Kinnman N; Lindmarker P; von Sydow M
Haemophilia; 2002 Mar; 8(2):129-35. PubMed ID: 11952848
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of chronic hepatitis C in special groups].
Bourlière M; Halfon P; Portal I
Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B238-47. PubMed ID: 12180296
[No Abstract] [Full Text] [Related]
7. A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy.
Younossi ZM; Mullen KD; Zakko W; Hodnick S; Brand E; Barnes DS; Carey WD; McCullough AC; Easley K; Boparai N; Gramlich T
J Hepatol; 2001 Jan; 34(1):128-33. PubMed ID: 11211889
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects.
Gardner S; Cutrell A; Elko-Simms C; Adkison K; Hamatake R; Walker J; Rodriguez-Torres M; Hong Z
Liver Int; 2014 Jul; 34(6):e89-95. PubMed ID: 24107072
[TBL] [Abstract][Full Text] [Related]
9. Clinical comparison of high-dose interferon-alpha2b with or without ribavirin for treatment of interferon-relapsed chronic hepatitis C.
Cheng PN; Chow NH; Hu SC; Young KC; Chen CY; Jen CM; Chang TT
Dig Liver Dis; 2002 Dec; 34(12):851-6. PubMed ID: 12643293
[TBL] [Abstract][Full Text] [Related]
10. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial.
Hayashi N; Izumi N; Kumada H; Okanoue T; Tsubouchi H; Yatsuhashi H; Kato M; Ki R; Komada Y; Seto C; Goto S
J Hepatol; 2014 Aug; 61(2):219-27. PubMed ID: 24727123
[TBL] [Abstract][Full Text] [Related]
11. Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial.
Van Vlierberghe H; Leroux-Roels G; Adler M; Bourgeois N; Nevens F; Horsmans Y; Brouwer J; Colle I; Delwaide J; Brenard R; Bastens B; Henrion J; de Vries RA; de Galocsy C; Michielsen P; Robaeys G; Bruckers L
J Viral Hepat; 2003 Nov; 10(6):460-6. PubMed ID: 14633181
[TBL] [Abstract][Full Text] [Related]
12. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
Hadziyannis SJ; Sette H; Morgan TR; Balan V; Diago M; Marcellin P; Ramadori G; Bodenheimer H; Bernstein D; Rizzetto M; Zeuzem S; Pockros PJ; Lin A; Ackrill AM;
Ann Intern Med; 2004 Mar; 140(5):346-55. PubMed ID: 14996676
[TBL] [Abstract][Full Text] [Related]
13. Interferon plus ribavirin in HIV-infected patients with chronic hepatitis C.
Pérez-Olmeda M; González J; García-Samaniego J; Arribas JR; Peña JM; Soriano V
J Acquir Immune Defic Syndr; 1999 Nov; 22(3):308-9. PubMed ID: 10770353
[No Abstract] [Full Text] [Related]
14. Comparison of the efficacy of ribavirin plus peginterferon alfa-2b for chronic hepatitis C infection in patients with and without coagulation disorders.
Honda T; Katano Y; Kuzuya T; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Ishikawa T; Toyoda H; Kumada T; Yamamoto K; Matsushita T; Kojima T; Takamatsu J; Goto H
J Med Virol; 2013 Feb; 85(2):228-34. PubMed ID: 23160930
[TBL] [Abstract][Full Text] [Related]
15. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.
Carriero D; Fabrizi F; Uriel AJ; Park J; Martin P; Dieterich DT
Int J Artif Organs; 2008 Apr; 31(4):295-302. PubMed ID: 18432584
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin.
Fried MW; Peter J; Hoots K; Gaglio PJ; Talbut D; Davis PC; Key NS; White GC; Lindblad L; Rickles FR; Abshire TC
Hepatology; 2002 Oct; 36(4 Pt 1):967-72. PubMed ID: 12297845
[TBL] [Abstract][Full Text] [Related]
17. Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.
Welzel TM; Morgan TR; Bonkovsky HL; Naishadham D; Pfeiffer RM; Wright EC; Hutchinson AA; Crenshaw AT; Bashirova A; Carrington M; Dotrang M; Sterling RK; Lindsay KL; Fontana RJ; Lee WM; Di Bisceglie AM; Ghany MG; Gretch DR; Chanock SJ; Chung RT; O'Brien TR;
Hepatology; 2009 Jun; 49(6):1847-58. PubMed ID: 19434718
[TBL] [Abstract][Full Text] [Related]
18. Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients.
Brouwer JT; Nevens F; Bekkering FC; Bourgeois N; Van Vlierberghe H; Weegink CJ; Lefebvre V; Van Hattum J; Henrion J; Delwaide J; Hansen BE; Schalm SW;
J Hepatol; 2004 Apr; 40(4):689-95. PubMed ID: 15030987
[TBL] [Abstract][Full Text] [Related]
19. High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C.
Mancuso ME; Rumi MG; Santagostino E; Linari S; Coppola A; Mannucci PM; Colombo M;
Haematologica; 2006 Oct; 91(10):1367-71. PubMed ID: 17018386
[TBL] [Abstract][Full Text] [Related]
20. Progress on the treatment of hepatitis C.
Nierengarten MB
Lancet Infect Dis; 2003 Dec; 3(12):748. PubMed ID: 14664249
[No Abstract] [Full Text] [Related]
[Next] [New Search]
